CrisprBits, a biotechnology startup headquartered in Bengaluru with a 7,300-sq-ft R&D and prototype facility, has successfully closed a US $3 million Pre-Series A funding round. The round was led by Spectrum Impact, along with participation from existing backers such as VJ Technologies Group’s Vijay Alreja Family Office, and new investors including the promoter family of HBL Engineering. 

CrisprBits will channel the funds primarily into scaling and commercialising its PathCrisp molecular-diagnostics platform which aims to deliver rapid, accurate detection for diseases such as sickle cell, typhoid, and antimicrobial-resistant infections. It also plans to increase manufacturing capacity to support high-volume testing across human health, food safety, and animal-health applications. 

In parallel, the startup intends to advance its synthetic-biology efforts under its EdiCrisp platform  a CRISPR-driven strain-engineering system  with early focus on biofuel production optimisation and sustainable biotech solutions. The broader vision spans diagnostics, genome-engineering, and therapeutics, positioning CrisprBits as a multi-modal biotech innovator. 

According to CEO Vijay Chandru, this funding and global ambitions reflect a mission to “rewrite biology and reimagine the planet.” The company plans to start rolling out its diagnostic products soon  with an eye on licensing for international markets including Africa and Latin America within the next six months.